Revolution Medicines, Inc. (RVMD)

Revolution Medicines' stock has increased significantly, by 133.01% over the past six months and 46.57% in the past month. Positive Phase 3 trial results for daraxonrasib in metastatic pancreatic cancer, demonstrating an unprecedented overall survival benefit, triggered analyst price target increases. The FDA authorized early access to Revolution Medicines' pancreatic cancer pill and granted Breakthrough Therapy Designation for zoldonrasib and elironrasib, and Priority Designation for a cancer treatment. The company reported a wider-than-expected net loss for Q1 2026 and raised its operating expense guidance. The stock saw movement due to speculation about a potential acquisition by Merck, but the stock pulled back after reports that Merck was no longer looking to buy the firm.

There is no specific information available regarding demand seasonality for Revolution Medicines, Inc.'s products and services. Demand is primarily driven by the prevalence of RAS-addicted cancers and the success of its clinical trials, leading to regulatory approvals and commercialization, and is not subject to traditional seasonal fluctuations.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers, operating within the Healthcare sector and Biotechnology industry. The company's pipeline focuses on RAS(ON) inhibitors, including Daraxonrasib (RMC-6236) in Phase 3 trials for metastatic pancreatic cancer, Elironrasib (RMC-6291) in early clinical development for solid tumors, Zoldonrasib (RMC-9805) in Phase 3 trials evaluating its combination with daraxonrasib, RMC-5127 in clinical development, and RMC-0708 (Q61H) and RMC-8839 (G13C) also in clinical development. The company also develops RAS companion inhibitors.

Revolution Medicines, Inc. is headquartered in Redwood City, California, United States, and has established a broad geographic footprint to support its clinical trials and mitigate potential impacts related to the availability of subsequent therapies.

Revolution Medicines' brand reputation has been bolstered by positive clinical trial results and regulatory milestones, including the successful Phase 3 trial of daraxonrasib for pancreatic cancer and FDA Breakthrough Therapy Designations for its drug candidates. The publication of Phase 1/2 clinical data for daraxonrasib in the New England Journal of Medicine reinforces its scientific credibility. Analyst sentiment is overwhelmingly positive. Acquisition rumors had a mixed impact, initially boosting the stock but potentially raising questions after talks cooled, though the company's clinical success has largely overshadowed this.

Revolution Medicines, Inc. has a diverse ownership structure, with 416 institutional owners and shareholders holding a total of 186,544,196 shares. Approximately 94.34% of the stock is held by institutions, while insiders hold 8.20%, and public companies and individual investors hold 64.13%. Major institutional shareholders include Vanguard Group Inc., Farallon Capital Management Llc., Janus Henderson Group Plc., Baker Bros. Advisors Lp., BlackRock, Inc., Wellington Management Group Llp., Paradigm Biocapital Advisors LP., Bellevue Group AG, and State Street Corp.